These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35154988)

  • 1. Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review.
    Sumbly V; Landry I; Rizzo V
    Cureus; 2022 Jan; 14(1):e21018. PubMed ID: 35154988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
    Uson Junior PLS; Borad MJ
    Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.
    Müller C; Franke S; Reisländer T; Keitel V; Venerito M
    Case Rep Oncol; 2024; 17(1):753-762. PubMed ID: 39015644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
    Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
    Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
    Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.
    Fostea RM; Fontana E; Torga G; Arkenau HT
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T; Quesada S
    Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract]   [Full Text] [Related]  

  • 11. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
    Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Soldà C; Cito P; Nasti G; Lavacchi D; Zanuso V; Rizzato MD; Zaniboni A; Ottaiano A; Persano M; Cornara N; Scartozzi M; Cascinu S; Casadei-Gardini A
    Ther Adv Med Oncol; 2023; 15():17588359231171574. PubMed ID: 37457302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L; Lowery M
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.
    Cleary JM; Rouaisnel B; Daina A; Raghavan S; Roller LA; Huffman BM; Singh H; Wen PY; Bardeesy N; Zoete V; Wolpin BM; Losman JA
    NPJ Precis Oncol; 2022 Sep; 6(1):61. PubMed ID: 36056177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
    Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
    Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.
    Akita M; Sofue K; Fujikura K; Otani K; Itoh T; Ajiki T; Fukumoto T; Zen Y
    HPB (Oxford); 2019 Feb; 21(2):226-234. PubMed ID: 30170977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies for Perihilar Cholangiocarcinoma.
    Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
    Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
    J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.
    Liu Y; Wang Y; Yu Y; Luo H; Zhen M; Ren J
    Front Surg; 2022; 9():1037310. PubMed ID: 36873806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
    Rizzo A; Brandi G
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.